Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
07:10am, Thursday, 07'th Aug 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership.
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 07'th Aug 2025
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
07:00am, Thursday, 07'th Aug 2025
Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue g
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
11:01am, Wednesday, 06'th Aug 2025
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?
10:56am, Friday, 01'st Aug 2025
The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?
12:10pm, Thursday, 24'th Jul 2025
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?
01:11pm, Monday, 14'th Jul 2025
CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CorMedix Analyst Says Investors Could Be Further Rewarded
02:24pm, Monday, 30'th Jun 2025
Last week, CorMedix Inc. CRMD said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.
CorMedix Seems Significantly Undervalued
02:14pm, Monday, 30'th Jun 2025
CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per sh
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
09:09am, Friday, 27'th Jun 2025
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
08:00am, Friday, 27'th Jun 2025
BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Thursday, 26'th Jun 2025
BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
11:01am, Tuesday, 24'th Jun 2025
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
02:51pm, Monday, 23'rd Jun 2025
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath.
CorMedix inc. Announces Customer Implementation
07:30am, Monday, 23'rd Jun 2025
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
